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 PATHOGENESIS AND TREATMENTS  
JESSICA H. WONG  
ABSTRACT 
 Postpartum depression (PPD) is a mood disorder that affects women shortly after 
the birth of their newborn. Prevalent symptoms include sadness, anxiety, fatigue, and lack 
of interest in activities that used to be pleasurable. Severe cases may include suicide 
ideation. While the pathogenesis and treatment methods are similar to major depressive 
disorder (MDD), it is not until recently that individual research has been performed to 
further understand PPD and its origins as well as efficacy of treatments on mothers with 
their wavering biology.  
Risk factors that are statistically significant in contributing to a higher risk of PPD 
include biological and genetic predispositions, environmental factors such as 
demographics, and most importantly, the mother’s previous mental history. Clinicians 
suggest treatment methods depending on the severity of the case and the mother’s 
lifestyle. Psychotherapy is the first-line treatment recommended to mothers with mild to 
moderate PPD; this is also a favorable choice for mothers breastfeeding as all 
antidepressants can secrete into breast milk. Antidepressants fall under several 
classifications, with selective serotonin reuptake inhibitors (SSRIs) being the optimal 
choice as they produce less side effects compared to the others. Mothers with a previous 
mental history or severe PPD are immediately recommended antidepressants as the 
therapy of choice.  Electroconvulsive therapy (ECT), while controversial, has become a 
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more prominent option for mothers with severe PPD or for patients who simply want 
results sooner.  
Meta-analyses performed explore the origin of PPD and compare treatments 
currently in place. Similar confounding variables arise time and time again in these 
studies; region, local demographics, and self-report surveys make it difficult to apply data 
from one city, much less another country, to another. Studies with a large population of 
people of color or areas where seeking mental health counseling is looked down upon 
show large numbers of subjects dropping out of studies midway. The accuracy of data 
from self-report surveys is also questionable. As research continues to find more effective 
treatments and better comprehend the biological aspect of PPD, an increased 
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Postpartum depression (PPD), also known as peripartum depression by the DSM-
V, is a common complication mothers face. It falls under major depressive disorder 
(MDD), a mental health disorder characterized by continual depressed mood and/or loss 
of interest in life and activities. This mental illness may debilitate the mother’s ability to 
go about her day, as well as her relationship with family and friends. With a specifier of 
postpartum onset within one month after childbirth, postpartum women are regularly 
evaluated two weeks to six months after delivery and screened in order to identify 
possible PPD1. It should be noted that PPD differs from peripartum depression, wherein 
the latter refers to the mother having depression while pregnant. However, the term 
“postpartum onset” has been criticized, as many PPD episodes diagnosed actually existed 
during pregnancy.  Therefore, the DSM-V now classify major depressive episodes “with 
peripartum onset”; this will include symptom onsets during pregnancy or in the month 
after birth2.  
PPD prevalence peaks around two to six months postpartum. While new mothers 
may only experience mild depressive symptoms, 10-15% will encounter more severe 
symptoms that impair their role as caregivers to their newborn child1. If left untreated, 
impaired mother-child bonding, unsuccessful breastfeeding, marital discord, and worse 
offspring cognitive and social development will likely result3.  Infants of depressed 
mothers often have troublesome temperament, impaired self-regulation and additional 
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behavioral problems on top of it all1. This causes the stress of newborn care to be 
heightened and postpartum recovery slowed further.  
PPD symptoms can overlap with different diagnoses; clinicians must be careful in 
determining whether comorbidity is at play. Other psychiatric conditions that may 
overlap with PPD or have similar symptoms as PPD include post-partum blues, post-
partum psychosis, bipolar disorder (Type I or II), and bereavement4. Post-partum blues 
occur in 50-80% of new mothers; signs and symptoms are similar to PPD, arising days 
following birth. The sudden change in mood and behavior in the mother is mild, usually 
resolving itself within a week1.  If left unmonitored, up to 25% of patients will then 
develop PPD5. Post-partum psychosis, though rare, is a serious condition with signs 
emerging one to four weeks after delivery. Specific symptoms include delusions, 
hallucinations, severe and rapid mood swings, sleep disturbances, and being obsessively 
preoccupied with the newborn4. Bipolar disorder and MDD (unipolar) have similar, 
general diagnostic criteria; however, a history of mixed, manic, or hypomanic episodes 
discriminate between the two2. Clinicians must be especially careful when diagnosing a 
new mother between the two, as the pharmacotherapy vastly differ. Finally, bereavement 
may occur due to a neonatal death or to a loss of a pregnancy. The sudden emergence of 
intense grief, poor sleep and appetite is akin to PPD; if significant enough, bereavement 
may propel the mother into PPD4.  
PPD has a high prevalence; early detection and treatment improves prognosis for 
both the mother and newborn. This paper will provide a background on MDD, including 
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its diagnosis and risk factors that explain why certain individuals are more prone to 
having MDD. Diagnosis methods and current treatments available for PPD will be 
discussed and compared to determine which is most effective in treating mothers.  
 
A. Major Depressive Disorder (MDD) 
Depression is a prevailing mental disorder, as well as a leading cause of burden in 
the Global Burden of Diseases6.  The name alone encompasses various depressive 
disorders, including MDD, minor depression, and persistent depressive disorder 
(dysthymia). More than 264 million people are affected globally as of 2017, with this 
number estimated to be higher due to underreporting7.  Prevalence rates vary by age, 
gender, and economic status, amongst other categories; these rates peak in older 
adulthood, females, and lower to lower-middle class.  
Major depressive episodes (MDE) may be part of MDD or an isolated episode, 
varying in severity depending on functional domain impairment.  It is a period identified 
by MDD symptoms (Table 1)8. With no single definitive cause of MDD, biological, 
psychological, and social sources could contribute to the disorder. Many times, MDD 
occurs concurrent with other psychiatric and/or medical conditions. This may include the 
medication that is prescribed to either MDD or the concurrent condition (Table 2)9. 
Symptom severity must be considered when deciding on a proper treatment. Many of the 
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screening tests and questionnaires are graded on a severity scale. This correlates with the 
number of symptoms the patient falls under according to the DSM-5.  
 
Table 1: Primary DSM-IV depression disorders, criteria for adults: 
Symptoms present in each depression episode and disorder. Patient must be experiencing 
at least five of the following signs and symptoms for most of the day, nearly every day for a 
minimum of two weeks. At least one of the symptoms must include depressed mood or loss 
of interest or pleasure. While the newest edition of the Diagnostic and Statistical Manual of 
Mental Disorders, 5th Edition (DSM-V) replaced the class of Mood Disorders as Depressive 
Disorders, the symptoms and requirements have remained the same (Taken from O’Connor 




Table 2:  Selected differential diagnosis of MDD: 
Possible reasons a patient may score positively on a screen test. It is not a complete list, but 
rather standard considerations for clinicians in order to prevent a misdiagnosis (Taken from 
Patricia and Price, 2020)9.  
 
 
Various MDD screening methods exist; which clinicians choose to use will 
depend on the primary care setting. While screening is not recommended for every 
patient, as this would increase the percentage of false positives, clinicians are reminded to 
pay attention to high risk populations as those mentioned above. In addition, this would 
include patients with a past history of major depression and/or have new life-stressors. 
The most basic and quickest questionnaire used to screen for MDD would be the Patient 
Health Questionnaire-2 (PHQ-2, Table 3). This is a good choice for a fast-paced clinic 
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with a high influx of patients. The PHQ-2 simply has two questions, and these represent 
the two symptoms necessary in order for one to be diagnosed with MDD according to the 
DSM-5 10. If at least one of the two questions receive a high score of two or three, 
physicians will perform other screenings such as a the PHQ-9 (Table 4). The PHQ-9 
applies the same answering scale of zero to three as the PHQ-2; however, the questions 
now list the rest of the criterion of MDD as listed in the DSM-510. Unlike the PHQ-2, 
severity can be measured on a scale of zero to twenty-seven since there are nine 
criterions, each with a scale of zero to three. While it is a popular screening method and 
more accurate in comparison to the PHQ-2, some argue whether adding symptoms not 
listed in the DSM-5 would increase the questionnaire efficacy .  
 
Table 3: Patient Health Questionnaire- 2 (PHQ-2):  
The two questions that appear on the patient health questionnaire. According to the DSM-5, any 
person clinically diagnosed with MDE must display at least one of these two symptoms, if not 
both, for a minimum of two weeks. The short property of PHQ-2 allows physicians to give the 
screening without it being laborious. If a patient scores over 2 for either question, a longer 




Table 4: Patient Health Questionnaire-9 (PHQ-9): 
Questions a patient would have to answer if a physician decides to further screen him/her/them 
for MDD. The nine criterions listed represent MDD symptoms as detailed in the DSM-5. Like the 
DSM-5, MDD is only diagnosed if five or more of the symptoms apply, occurring for a minimum of 
two weeks.  In this case, the five or more symptoms must have a score of two or three with the 
exception of criterion 9 (Taken from Ng et al., 2020)10. 
 
 
Several factors can contribute to the development of MDD. Life-stressors such as 
school and work contribute to environmental factors, but genetics and bodily functions 
can also be partly responsible.  Trying to identify single genes associated with MDD has 
been proven difficult due to psychiatric illnesses being under polygenic influence, and 
those genes being affected by environmental exposures12. Candidate genes associated 
with known biological mechanisms and metabolic pathways have been useful in 
developing antidepressant drugs. From a survival fitness point of view, all forms of 
mental illness are associated with increased mortality of varying degrees, whether natural 
or not. In regards to reproductive fitness, most types of mental illness is correlated with 
reduced fertility (Table 5)12. Unipolar depression has a subtler effect on fertility 
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compared to other mental illnesses. The reduced fitness is seen through reduced survival 
and reproduction, extending to future generations who then become carriers for disease-
associated genetic variants. Compared to other mental illnesses, depression is moderate in 
population based samples, but larger in clinical based research with reliable assessment 
methods13.   
 
Table 5: Genetic epidemiology of selected types of mental illness:  
Above lists the life time prevalence (%), median age of onset (years), mortality ratios (>1 
represent increased mortality compared to the general population), fertility ratios (<1 represent 
decreased fertility compared to the general population), heritability (addictive genetic effects from 
twin studies), and index of paternal age effect (risk ratio for ten-year increase in fathers older than 
thirty). No paternal age effect data is available for anorexia nervosa and anxiety disorders. This 
table summarizes the reproductive disadvantage mental illnesses have over healthy candidates 
(Taken from Uher, 2020)12.  
 
Genetic measures may precipitate to larger bodily issues if not caught early 
(Figure 1)14. Three main categories of peripheral hormone-type factors are involved in 
the pathophysiology of MDD. They are neurotrophic factors and various growth factors, 
proinflammatory cytokines, and impaired regulation of the hypothalamic-pituitary-
adrenocortical (HPA) axis14. An example of each include serum brain-derived 
neurotrophic factor (BDNF), proinflammatory cytokine secretion, and impaired 
regulation of the HPA axis, respectively. Serum BDNF is decreased in patients with 
MDD15. Common attributes in individuals with MDD include feeling stressed and 
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depressed. Secretion and production of proinflammatory cytokines are increased 
compared to healthy individuals. Debilitated neuroendocrine response is seen through the 
combined dexamethasone-corticotrophin-releasing hormone test, proving altered 
regulation of the HPA system16.  This test requires individuals to orally take 1.5 mg 
dexamethasone at 23:00h the night before stimulation. The following day at 15:00h, a 
bolus of 100μg human CRH is administered intravenously. To determine plasma cortisol 
and ACTH, blood samples are drawn every fifteen minutes from 14:00h to 18:00h17. 
Overall, all three situations can be reversed through antidepressant treatments.  
 
 
Figure 1: Advances in neurobiology of MDD: 
A possible development of MDD in an individual. Genetic, heritable factors lead to the growth of 
molecular and neural issues, which then contribute to the severity of MDD (Taken from Kupfer et 





Neuroimaging studies have shown that areas of the brain responsible for emotion 
processing, emotion regulation, and reward seeking are impaired in people with MDD. 
Anatomically, this would include subcortical systems (amygdala, ventral striatum), 
medial prefrontal and anterior cingulate cortical regions, and lateral prefrontal cortical 
systems (Figure 2)14. These regions of the brain are part of a feedforward mechanism, 
providing information to the significance of external emotional stimuli. In individuals 
with MDD, there is an abnormally reduced ventral striatal activity in both adults and 
adolescents in relation to reward; this includes both the anticipation of an award and the 
process of receiving an award.   
Furthermore, there is a bias of attention towards negative emotional stimuli18. 
Another method used to measure neural activity of individuals with MDD is diffusion 
tensor imaging. This technique measures water diffusivity in different directions relative 
to white-matter fibers to construct whole-brain white-matter connectivity. Findings show 
abnormal prefrontal cortico-subcortical white-matter connectivity between regions of the 
brain that regulate emotion19. A meta-analysis of several MDD neuroimaging studies 
identified two contributing neural systems. One network is on the dorsolateral prefrontal 
cortex (PFC) and more dorsal regions of the anterior cingulate cortex. It is characterized 
by reduced activity in the resting state, and can be corrected with treatment. The second 
network centers on the medial PFC and subcortical regions. In MDD individuals, it is 
hyperactive to emotional stimuli, but normal after antidepressant treatment (Figure 3)20.  
Advances in treatment today include psychotherapies, antidepressants pharmacotherapy, 




Figure 2: Neural systems of relevance to MDD: 
Key anatomical regions that regulate emotion and reward processing.  Some regions lead to a 
voluntary response while others are automatically controlled. These systems conceptualized is a 
medial prefrontal-limbic network, with areas that can be modulated by serotonin or dopamine. 
DLPFC= dorsolateral prefrontal cortex. mPFC= medial prefrontal cortex. ACC= anterior cingulate 






Figure 3: Areas of significant differences in activation: 
Areas of the brain that show increased (red) or decreased (blue) activity across three different 
analyses when depressed patients were exposed to positive stimuli. The first row (a) illustrates 
brain activation increases and decreases in regions compared with controls (not shown). The 
second row (b) illustrates increases and decreases in regions of depressed patients taking 
antidepressants. The last row (c) illustrates increases and decreases in regions of depressed 
patients compared to healthy individuals when exposed to positive stimuli (Adapted from 




B. Risk Factors for PPD 
PPD is common, reported to occur in 15-85% of women within two weeks after 
giving birth. The term describes depressive episodes that occur within a year of delivery4. 
Generally, no intervention is needed. This occurrence, while seemingly natural, is 
monitored to ensure an early prognosis and treatment. Much like MDD, various factors 
can contribute to the severity and prolongation of PPD. Risk factors clinicians consider 
include genetic/biological disposition, environmental factors, and the mother’s previous 
mental health history.  
Some mothers may have a biological susceptibility to PPD. Many of the genes 
identified invoking an increased risk of depression in the general population affect the 
synthesis or metabolism of brain monoamines21. This has been termed the monoamine 
hypothesis to summarize dopamine (DA), serotonin (5-HT), and norepinephrine (NE)’s 
effect on mood in the central nervous system (CNS). Research on depression have 
traditionally focused on 5-HT.  
Made from the precursor tryptophan, 5-HT is stored in the presynaptic terminal 
until release into the synaptic cleft (Figure 4)22.  Any remaining 5-HT in the cleft is taken 
up by serotonin transporters (SERT) at the presynaptic neuron. The serotonin transporter 
gene is one of the most studied in MDD23. It contains two common length 
polymorphisms, 5-HTTLPR and STin2 VNTR (variable number tandem repeat), which 
may explain certain individual’s predisposition to MDD or PPD. A 43-base-pair insertion 
or deletion polymorphism, 5-HTTLPR polymorphism is in the SERT gene promoter 
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region21. If this 43-base-pair segment exists, the individual carries the long (l) allele; 
without this segment, they carry the short (s) allele. People usually have two copies of 
each gene. As a result, they may be homozygous for either long or short allele or 
heterozygous with one long, one short allele22.  
 The s allele is associated with lower transcriptional efficiency, slowing down the 
synthesis of SERT24. This reduces 5-HT uptake capacity as well as the speed 5-HT 
neurons respond to stimulation. Consequentially, increased 5-HT neurotransmission 
would occur in an attempt to speed up neuronic response and to compensate for the lack 
of pre-synaptic 5-HT storage25. Still not releasing a normal amount of 5-HT, an 
individual’s sensitivity to stress will be affected, such as observing an increase in his/her 
anxious behaviors. This is consistent with other findings that individuals with depression 
have reduced 5-HT uptake26.   
The other polymorphism, STin2 VNTR, is found in the second intron of the 
SERT gene and also affects transcriptional efficiency. It consists of seven (rare), nine, 
ten, or twelve short similar sequence repeats21. The nine and twelve segment repeats 
(STin2.9, STin2.12) lead to a higher expression of SERT compared to the ten segment 
repeat (STin2.10)27 . Individuals with the homozygous s 5-HTTLPR genotype experience 
greater incidence of depression when exposed to significant life stressors, exhibiting 
more depressive symptoms and higher rates of suicide ideation. Those with the 
homozygous l 5-HTTLPR genotype were less likely to be diagnosed with depression 




Figure 4: The serotonin (5-HT) synapse: 
Synthesis, packaging, and release of 5-HT between two neurons. Made from its precursor 
tryptophan, 5-HT is packaged and awaits release at the presynaptic neuron’s terminal. Following 
an action potential, 5-HT is released from the cleft, where it then binds to receptors on the 
postsynaptic neuron transducing signals. Any remaining 5-HT in the synapse is taken up by the 
presynaptic neuron by a transporter (SERT) (Taken from aan het Rot et al., 2020)22.  
 
 
Pregnant and postpartum women have larger concentrations of 5-HT and its 
metabolites in cerebral spinal fluid (CSF) and plasma compared to non-pregnant 
women29. Biochemically free (not total) tryptophan are also higher in pregnant women30.  
However, mothers with PPD have 50% lower platelet 5-HT levels than normal. Repeated 
restraint stress during the last week of pregnancy increases PFC 5-HT turnover31. In one 
study by Winokur et al., maternal behaviors were observed by altering monoamine levels 
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in Wistar-Kyoto (WKY) models of endogenous depression in Sprague-Dawley (SD) 
control rats. They measured levels of DA, 5-HT, NE within the medial PFC, striatum, 
nucleus accumbens, and medial preoptic area of WKY and SD mothers at three 
postpartum stages. In addition, they observed physical maternal behaviors, such as pup 
retrieval, lickings, body contact with the pup, and nest building. WKY mothers exhibited 
significant differences in intracellular levels of all three monoamines as well as severe 
deficit in maternal behaviors compared to SD mothers; they spent less time with their 
pups and demonstrated less active caregiving32. 
Neurotrophic factors are another area of study in the pathophysiology of 
depression. Stress has been shown to robustly reduce neurogenesis and neurotrophic 
factor gene expression in the brain33. BDNF, in particular, is a dimeric protein found 
throughout the brain, with especially high quantity in the hippocampus and cerebral 
cortex. Postmortem studies show depressed subjects with reduced levels in these areas 
compared to a healthy individual34. Hippocampal lesions influence anxious and 
depressive behaviors; these same depressed subjects have smaller hippocampi than 
normal. Rodent studies also found different types of stresses decrease BDNF expression 
in limbic brain regions15. To test humans’ BDNF levels, blood samples are taken in order 
to measure serum, plasma, and whole blood BDNF content. When compared to controls, 
depressed patients have lower serum BDNF. Furthermore, meta-analysis shows distinct 
indication for an association between serum BDNF and depression status35.  
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A common polymorphism in the gene coding for BDNF produces two alleles, Val 
and Met. This polymorphism affects intracellular BDNF transport and secretion36.  
Individuals with the variant Met have a comparatively smaller hippocampus at birth. 
They display hippocampal hypoactivity when resting, hyperactivation when learning, and 
poor hippocampus-dependent memory37. All in all, this may contribute to hippocampal 
hypersensitivity to stress. If an individual, exposed to environmental stressors, were to 
have the Met variant of BDNF and was also homozygous for the short SERT allele, they 
would have an increased vulnerability to depression compared to individuals having only 
one of these factors. If this individual was a mother with a newborn, she would be at high 
risk for PPD.  
The HPA axis is a feedback loop involving the hypothalamus, pituitary, and 
adrenal glands (Figure 5)38. It controls reactions to stress, adapting the neuroendocrine 
response when necessary. When an individual is met with either a physical or emotional 
stressor, this feedback loop activates. The hypothalamus secretes corticotropin-releasing 
hormone (CRH) and arginine vasopressin (AVP), which act on the pituitary stimulating 
adrenocorticotropin hormone (ACTH) release. CRH is a 41 amino acid peptide found 
throughout the CNS, playing a critical role in regulating the HPA axis, and is a 
fundamental regulator of the mammalian stress response39. With CRH interacting with 
pituitary receptors, ACTH is secreted and carried in the blood. Arriving at the adrenal 
cortex and interacting with its receptors, production of cortisol is stimulated. Cortisol is 
the adrenal glucocorticoid stress hormone in humans and primates; a similar hormone 
found in other animals is corticosterone. While most of the cortisol circulating is protein 
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bound, only free cortisol is able to bind to receptors.  There are at least two types of 
intracellular receptors it could possibly bind. Type I receptors, mineralocorticoid 
receptors, have the highest affinity for cortisol and are most likely to bind before Type II 
glucocorticoid receptors 38. The HPA negative feedback loop allows cortisol to act on the 
hypothalamus by inhibiting the release of CRH and maintaining the homeostasis of 
cortisol. This type of negative feedback depends on the concentration of cortisol. Another 
negative feedback loop, identified as fast feedback, depends not on the absolute 
concentration of cortisol but rather on its change in concentration and on receptors 
expressed in higher brain centers38.  
 
 
Figure 5: The Hypothalamic-Pituitary-Adrenal (HPA) Axis: 
A simplified version of how the HPA feedback loop acts. The sympathetic nervous system is 
immediately activated when a person is presented with a stressor, causing a release of 
epinephrine and norepinephrine. Seconds later, the HPA axis is activated. Responding to the 
elevated neurotransmitter levels, corticotropin-releasing hormone (CRH) and arginine 
vasopressin (AVP) initiate a cascade of events that eventually stimulating the adrenal glands 
causing a release of cortisol. A negative feedback response occurs in relation to the 
hippocampus and higher centers (Taken from Varghese and Brown, 2020)38.  
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Individuals either depressed or predisposed to depression have an excess of 
cortisol and dexamethasone suppression test (DST) nonsuppression. The DST is 
performed to examine levels of cortisol, ACTH, or CRH release. Synthetic corticosteroid 
DEX binds to the ACTH receptor and is given to an individual in the evening, and 
cortisol samples are collected the next day. A healthy individual would show decreased 
endogenous cortisol release, due to the DEX negative feedback. In cases where cortisol 
does not decrease, and is usually elevated, the patient has DST nonsuppression38.  DST 
suppression resumes when mood symptoms resolve.  
Like cortisol, CRH strongly influence mood. Not only is it the primary regulator 
of ACTH release, it also plays an important role in regulating the autonomic nervous 
system, learning, memory, feeding, and reproduction related behaviors40. When 
administered to primates, CRH induces depression symptoms, including suppressed 
appetite, increased huddling and lying down, and disrupted sleep41. In MDD patients, 
elevated CRH cerebrospinal fluid concentrations have been reported. Overall, elevated 
CRH and ACTH appear to be a state rather than a trait marker; levels eventually 
normalize if depression is treated for38. Combined with environmental factors, stressful 
experiences may lead to HPA axis changes and increased vulnerability in individuals.   
In combination with these genetic factors that contribute to a mother’s 
predisposition to PPD, environmental factors can not only be stressors themselves but 
also influence those biological factors. As mentioned above, individuals homozygous for 
the s SERT allele are predisposed to depression compared to others who are heterozygous 
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or l homozygous, only if they are exposed to environmental stressors at some point in 
their life.  Simply being homozygous for the s allele does not induce the individual to be 
depressed. Other environmental stressors that have been studied include a mother’s 
demographics and social support.  
In 2004, Robertson et al. performed a meta-analysis on risk factors for PPD. 
Incorporating results from over seventy studies and twelve thousand research subjects, 
effect sizes were reported in terms of Cohen’s d. A d of 0.2 indicated a small relationship, 
0.4 a moderate relationship, and 0.8 a strong relationship42. Two meta-analyses they 
referred to were conducted by O’Hara and Swain and Beck, focusing on certain clinical 
and social risk factors (Table 6)42. According to their research, life events, social support, 
and mother’s previous mental history are strong factors that predict whether the mother 
will have PPD. Life events could include death of a loved one, relationship break up, job 
loss, or moving homes. There has been difficulty correlating specific life stressors to PPD 
risk; retrospectively data collecting could lead to overreporting of events by research 
participants trying to find a reason to explain their PPD. However, some linearity was 
found in O’Hara and Swain’s meta-analysis. Studies in Britain and North America had 
strong associations between PPD and recent life events, whereas Asian studies did not 





Table 6: Risk factors for PPD:  
Clinical and social variables from various studies, including meta-analyses performed by O’Hara 
and Swain and Beck. The sample sizes for each factor studied is listed. Effect size is in terms of 
Cohen’s d: 0.2 indicate a small relationship, 0.4 a moderate relationship, 0.8 a strong relationship 





 In Beck’s meta-analysis update, eighty-four studies examined thirteen predictors 
of PPD (Table 7)44. A fail-safe number is given for each subset, which refers to the 
minimum number of unpublished studies reporting nonsignificant findings needed in 
order to overturn the conclusions in this study. A reasonable tolerance level was reached 
for each predictor. Homogeneity tests identify outliers in any of the thirteen predictors; a 
nonsignificant test indicates no outliers. If outliers are calculated for any of the subsets, 
they are removed and a separate homogeneity test is performed on these outliers. None of 
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the secondary meta-analyses in this report had homogenous outliers. The 95% confidence 
interval determines whether the average effect size includes zero or not. Here, none of the 
confidence intervals in this meta-analysis contained zero. The strongest predictors of PPD 
include mother’s own mental health during the pregnancy and childcare stress44. New 
significant predictors not previously studied from this meta-analysis consist of marital 




Table 7: Profile statistics of PPD predictors meta-analysis: 
Thirteen significant predictors of PPD. The fail-safe number is the minimum number of 
unpublished studies reporting nonsignificant findings that would be needed in order to invalidate 
the conclusions reached in the meta-analysis. In this meta-analysis, a reasonable tolerance level 
was met by the fail-safe numbers for all thirteen subsets. Homogeneity test was performed to 
identify any outliers; no secondary meta-analyses for outliers were homogenous. None of the 
predictors have an r=0 under a 95% confidence interval; results were significant (Taken from 






Up until the early 2000s, little research was done to determine the relationship 
between social class and PPD, or whether there exists a relationship. Theoretically, the 
stress process model relates social status to different exposures of stress, factors that 
modulate said stress, and health outcomes. In accordance with this model, an individual 
with a lower status would experience increased stress with less coping resources, leading 
to increased depressive symptoms. Often studies examining social class and PPD also 
took into consideration ethnicity and race.  
Longitudinal studies were performed on over four thousand women in Idaho, 
United States during the first three years postpartum. They found that there is significant, 
albeit small, correlation between socioeconomic status (SES) and PPD. A logistic 
regression analyzed the relative importance of income, education, and educational 
prestige; income was concluded to be linear. When comparing the extremes of the strata, 
PPD in women with an annual income of less than $10,000 is 28.3%, compared to the 
6.7%  prevalence rate in women with an annual income greater than $70,000; the 
prevalence rate difference is more than four times greater45. In financially impoverished 
states, low income women cope with substandard living situations, lack of access to 
healthcare, and increased exposure to crime. To have to care for a newborn in an already 
stressful environment further stretches their limited economic resources. While results 
show SES is a statistically significant risk factor, poverty alone is not sufficient to explain 
depressive symptoms.  
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In a separate study, upper middle class and low-income participants were 
recruited from Northern California. Almost two hundred first time mothers were assessed 
for depressive symptoms in their third trimester, and once a month for three months 
postpartum.  The sample was split between those with a monthly income less than 
$30,000, and those greater. On average, those with a monthly income of less than 
$30,000 were younger and more ethnically diverse. Women falling in this criterion 
tended to live in larger households, and were less likely to be college-educated, married, 
or employed. Independent t-tests and chi tests were used to identify group differences; 
results showed low SES was associated with increased depressive symptoms during all 
but the first month postpartum. Women who, in addition to being low income, were 
unmarried, unemployed, and received less than a college education were eleven times 
more likely to have clinically elevated depression scores three months postpartum46.  
Amongst the low-income women, racial and ethnic disparities may further explain 
a mother’s risk to PPD.  A retrospective cohort study in New Jersey, United States 
recruited 29,601 Medicaid women who identified as white, black, or Latina. This study 
excluded women with bipolar disorder, schizophrenia, or a prenatal history of mental 
illness to better characterize the relationship between racial differences and PPD amongst 
low SES mothers. Using patient-level logistic regression models and Cox proportional 
hazard models to control for covariates and racial differences respectively, Kozhimannil 
et al. found 9% of white women initiated antidepressants or mental health counseling in 
the six months after delivery, compared to 4% of black women and 5% Latinas. 
Markedly larger proportion of white women, 44%, followed up on initial antidepressant 
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use, compared to 23% of blacks and 27% of Latinas47. The disparity amongst the three 
groups may not be that blacks and Latinas were less likely to be diagnosed with PPD; 
rather this could reflect stark racial-ethnic disparities related to outreach, detection, and 
service provision to mental health care. A cultural consideration should be recognized in 
which there may be a taboo in seeking mental health care, resulting in under-reporting of 
PPD in mothers of other ethnicities.  
Outside of a mother’s demographic, her familial and social support are important 
environmental risk factors that have been studied extensively. Social support can come in 
different forms; informational support comes as advice and guidance, instrumental 
include practical help or assistance, and emotional support produces empathy42. Studies 
consistently report a negative correlation between PPD and emotional and instrumental 
support48 49. However, the amount of support and what a mother defines as support 
varies. This is slightly accounted for due to the fact depressed individuals tend to view 
everything more negatively, including the level of support received.  
One of the most important PPD risk factors clinicians review is the patient’s 
previous mental history, including their personality inclination. Women who are naturally 
defined as anxious, nervous, or a worrier were significantly more likely to develop PPD. 
Similarly, women with a more pessimistic or easily irritable personality were at a higher 
risk than the average women for PPD3. Post-partum women with a history of depression 
are at a higher risk for anxiety and stress50. A nationwide prospective cohort study of 
women in Sweden from 1997 through 2008 was performed to study the relative risk of 
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clinical depression within the first year postpartum. Relative risk (RR) of PPD was 
estimated with incidence rate ratios from Poisson regression models fitted to the data. To 
interpret results, figures listing rates of PPD (cases/10,000) by month compared women 
with and without a depression history. Poisson regression models were fitted with the 
first month postpartum as a reference; RR of PPD was calculated each month after 
delivery. The interaction between history of depression and maternal obstetrics and 
prenatal conditions was tested with two-sided Wald Type Confidence Intervals at a 10% 
level of significance.  707,701 subjects were included in this study; within the first year 
after delivery, 4,397 cases of PPD arose (62 per 10,000). Both among women with and 
without a history of depression, PPD rates dropped dramatically after the first month 
postpartum (Figure 6)51. Compared to women without a history of depression, there was a 
statistically increased risk for those with such a mental history; RR = 21.03. A history of 





Figure 6: Rate of PPD one year postpartum: 
PPD rates (cases/10,000) during the first year postpartum between women who have and do not 
have a history of depression. PPD rates drop drastically the first month for both cohorts, 






C. Diagnosis and Screening 
According to the DSM-V, PPD is defined as a major depressive episode after 
delivery that must be persistent for at least two weeks within a month following delivery. 
During this period, the mother must express depressed mood and/or loss of interest in 
daily activities, in addition to five associated symptoms exhibited by individuals with 
MDD as mentioned above2. Currently, no definitive biologic measure has been found to 
cause or predict possible postpartum baby blues or PPD52. As a result, clinicians have 
turned to various screening methods in order to improve rates of PPD diagnosis and 




One of the most popular methods is the Edinburgh Postnatal Depression Scale 
(EPDS) score, which is used both during the pregnancy and postpartum 4. Completed in 
only five minutes, this self-report has a list of ten statements that the subject must rank 
from zero to three, based on their experience the past week.  An EPDS greater than or 
equal to thirteen is used as a cutoff point; women with this score are at risk for MDD and 
have a more difficult time recovering (Figure 7)53. A similar EPDS test is given to the 
mother’s partner, the EPDS-P1. This allows the clinician to consider other factors that 
could possibly contribute to the PPD. Risk factors include whether the mother lacks 
emotional support, closeness with her partner, and/or have any sexual dissatisfaction.  
 
Figure 7: Change in EPDS scores  
improvement on EPDS scores depending on whether the women had a score larger or smaller 
than thirteen previously. Compared to women who scored less than thirteen, those with scores 





Other screening questionnaires are also offered, such as the Center for 
Epidemiologic Studies of Depression instrument (CES-D), Patient Health Questionnaire 
(PHQ-9), and Postpartum Depression Screening Scale (PDSS)54. The CES-D is a twenty-
item questionnaire with high specificity and sensitivity. Participants must respond on a 
scale of zero to three how closely they associate with the listed statement. It is the 
screening of choice for depression in both culturally diverse populations and adolescent 
mothers (Table 8)55.  
  The PHQ-9, another popular screening method, is a shorter version of the official 
PHQ (Table 4)10. This method can effectively identify whether a patient in primary care 
(and obstetrical settings) has MDD, as mentioned previously. The PDSS has an initial 
screening of seven items. These items cover seven different categories: sleeping/eating 
disturbances, anxiety, emotional changes, cognitive impairment, loss of self, shame, and 
suicide-ideation56. Depending on the score, patients may receive a longer survey with 
additional items, for a total of thirty-five items. Those scoring extremely high, greater 
than eighty, suggest a risk for MDD or highly predictive for MDD. Which screening 
method clinicians choose will depend on their own judgment. It is to note all the 
aforementioned screening methods increase rates at which clinicians can diagnose and 
treat PPD; screening should not be considered a substitute for a detailed clinical 





Table 8: The Center for Epidemiologic Studies Depression Scale (CES-D Scale): 
The CES-D Scale measures depression severity through twenty statements.  The specifiers can 
be grouped into dysphoria, anhedonia, appetite, sleep, concentration, guilt, fatigue, agitation, and 
suicide ideation. The possible range of score is zero to sixty; higher scores indicate more 





CURRENT TREATMENT METHODS 
  
 
Once PPD is identified, treatment is started soon after. The more prolonged the 
wait, the higher the risk for a lengthy illness that could lead to impaired functioning, 
treatment resistance, and suicide. Evidence-based mainstays of PPD treatment is similar 
to those given to individuals with MDD; it has revolved around psychotherapy and 
antidepressants, at times coupling the two. Results have shown high effectiveness and use 
of either has been prevalent. While public awareness of PPD has increased, the majority 
of postpartum women do not seek mental health care57. Due to the high public health 
cost, more accepted strategies to treat mood symptoms have been developed. This 





 Therapeutic techniques and counseling are popular treatment methods for many 
mental health disorders, most commonly mild to moderate depression and anxiety. In the 
treatment of PPD, mothers have frequently turned to cognitive behavioral therapy (CBT), 
interpersonal psychotherapy (IPT), or electroconvulsive therapy (ECT). The choice is 
determined by a couple of factors, such as severity of the patient’s symptoms and how 
much time the individual can put aside for therapy sessions.  
 CBT is based on the theory that depression is caused by negative thoughts about 
others and self. It interlaces the relationships between emotion, cognition, and behavior. 
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Three aspects of cognition are highlighted by this theory: automatic thoughts, cognitive 
distortions, and underlying beliefs or schemas58. When these aspects are left untreated, 
they snowball into ideas with severe consequences, such as self-harm or suicide. CBT is a 
first-line treatment for PPD due to the flexibility of its application. CBT is a structured, 
goal-oriented form of therapy, the approach is hands-on and practical. The therapist and 
patient build rapport to work toward the intention of improving unhealthy thought and 
behavioral patterns, eventually leading to improved mood and lifestyle. The practice is 
customized to adapt to each individual’s needs and current condition.  
CBT covers a large territory with different techniques used to focus on the 
treatment of the same condition. In a study by Stamou et al., seven components of CBT 
used to treat PPD in mothers with mild to moderate PPD were measured: 
psychoeducation, cognitive restructuring, problem-solving, behavior management, goal 
setting/achievement, stress management, and relaxation. They found the most frequently 
used interventions were psychoeducation and challenging negative thoughts and beliefs. 
Other techniques that followed closely behind were problem solving, goal setting, and 
behavior and stress management59. A separate study by Milgrom et al. examined the 
efficacy of internet CBT for women with PPD. This has become a new concept as fewer 
than 50% of women with PPD seek help. This more convenient access allows mothers to 
accept help in the privacy of her own home. In a randomized controlled trial, six sessions 
were provided to twenty-one women. Twelve weeks after enrollment, their diagnostic 
status was assessed and compared to day one; almost 80% of women who received 
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internet CBT treatment no longer met diagnostic criteria for depression60. Overall CBT is 
an effective first-line treatment option for mothers with PPD, both in-person or online.  
 IPT is an attachment and interpersonal theory that addresses interpersonal issues 
that are believed to be the root cause of depressive symptoms. The targets of treatment 
are biopsychosocial: psychiatric symptoms, interpersonal struggles, and social support. 
This model frames psychological difficulties as the body’s response to physical and 
emotional stressors. Rather than targeting the symptoms, the counselor focuses on the 
patient’s personality, biological built, and the environment they are surrounded by61. In 
the beginning phase, clinicians must differentiate between symptoms of depression 
versus postpartum blues. Goals are set to instill positive expectations. During the middle 
phase, intervention begins. IPT is used to associate the individual’s life experiences to 
specific problem areas that exist. The struggles they have may fall within three problem 
areas: interpersonal disputes, role transitions, and grief. In addition to understanding the 
mother during this time, the counselor attends to the evolving relationship the mother has 
with her newborn. It is important they guide mothers with PPD so they may develop a 
nurturing relationship with their child. Towards the last few sessions, therapeutic gains 
are reviewed, and diagnostic status is once again reviewed. If necessary, contingency 
plans are discussed62. 
 ECT is a treatment that clinicians use to treat severe depression, mania, and 
schizophrenia. The technique brings about neuro-physiological and neuro-chemical 
changes in the macro- and micro-environment of the brain. Small currents are sent 
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through the brain, triggering a brief seizure. The actual mechanisms involved in the 
therapeutic effect of ECT are not fully understood; numerous psychological, 
neurological, and biological theories have been put forth to attempt to explain its 
mechanism. These theories cover metabolic, chemical, and genetic factors63.  
 Neuroimaging techniques have shown ECT alters cerebral blood flow and brain 
glucose metabolism. After an ECT-induced seizure, regional cerebral blood flow 
subsequently declines and there is a spike in glucose metabolism. This increase in 
glucose metabolism is especially significant with mounting evidence showing patients 
with depression have significant hypometabolism in certain areas of the brain64. Besides 
these metabolic changes, changes in neurotransmitter levels have been observed. An 
enhanced release of several major neurotransmitters and neurochemicals occurs in the 
brain. A transient and selective increase in adrenocorticotrophic hormone, cortisol, and 
prolactin is observed, returning to baseline a few hours after ECT treatment. In due time, 
cortisol levels are reduced and normal. Whether this has a therapeutic role or is secondary 
to other changes in the brain is still unclear65.  The ECT epigenetic modifications may 
contribute to the therapeutic effect. Amongst the ECT effects, it has been demonstrated to 
induce Gadd45b, a gene that demethylates BDNF. This trophic activity involves 
neuroprotection and increased neuronal proliferation. Meta-analyses indicated that low 
serum BDNF concentrations in depressed patients returned to normal after ECT 
treatments63. While its underlying mechanism is not fully understood, the ECT 
application has been modified throughout the years and has been proven effective in 
treating psychiatric disorders.  
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B. Medication and Supplements 
 
 Mothers diagnosed with moderate to severe PPD and that are not breastfeeding 
can consider antidepressant medication. No single antidepressant has shown greater 
benefit over another in treating PPD. Antidepressant selection can be facilitated in 
individuals with a family history of positive results for a specific class of antidepressants. 
Classes available for clinician’s consideration include selective serotonin reuptake 
inhibitors (SSRIs), serotonin-norepinephrine reuptake inhibitors (SNRIs), tricyclic 
antidepressants (TCAs), and monoamine oxidase inhibitors (MAOIs). The most prevalent 
class prescribed for postpartum or prenatal depression are SSRIs66. Current 
antidepressant therapies require a sustained treatment of two to four weeks to be 
effective. This suggests adaptive changes in noradrenergic and serotonergic 
neurotransmission, as well as downstream neural adaptation such as the BDNF receptor 
signaling pathway. Synaptic monoamine level elevation alone is not responsible for the 
therapeutic effects67.  
 SSRIs act by inhibiting serotonin reuptake at the synaptic cleft, increasing 
serotoninergic signaling. Amplification of second messenger signals in downstream 
targets of central serotonergic, noradrenergic, and dopaminergic neurons can be involved 
in therapy. Chronic administration of antidepressant treatments have been shown to 
increase BDNF expression67. Six randomized clinical trials, with a total of 595 women 
with PPD, studied the efficacy of SSRI compared to other PPD treatments. Comparisons 
included CBT, community-based intervention, placebo, and tricyclic antidepressants. All 
treatments demonstrated higher response rates compared to placebo. Those treated with 
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SSRI had greater average changes on the depression scale overall, although it is to note 
findings were not always statistically significant67.  Two common SSRIs, fluoxetine and 
sertraline, also branded on the market as Prozac and Zoloft respectively, have been 
repeatedly tested against placebos. Subjects receiving 20g fluoxetine each day improved 
significantly more than those receiving placebo68. In a separate double-blind, placebo- 
and amitriptyline controlled study, both sertraline and amitriptyline subjects showed 
significantly greater improvement from baseline compared to placebo subjects; however, 
these two antidepressants produced differing side effects not seen in the  placebo group69.  
Most SSRI side effects are dose related and attributed to serotonergic effects. Nausea and 
gastrointestinal disturbances are two commonly reported side effects. Specific side 
effects vary depending on the type of SSRI; anxiety and insomnia are commonly reported 
by users of sertraline and fluoxetine. For long-time users, sexual dysfunction, weight 
gain, and sleep disturbance are some of the more troubling adverse effects70. 
 SNRIs are characterized by mixed action on both 5-HT and NE. The double 
polarity aims to achieve a higher effectiveness compared to SSRIs. Their adverse effects 
are limited, making them better tolerated for certain individuals. The limitation is due to 
the absence of affinity for muscarinic, histaminic and alpha1-adrenergic receptors; the 
drug also does not act on monoamine oxidase. An improved rate of response is observed, 
decreasing risk of relapse and recurrence in the long run71. Randomized controlled trials 
were performed to compare the efficacy of SSRIs versus SNRIs. Although few individual 
studies generated significant differences, meta-analyses suggest SNRIs may be more 
effective as a class. This difference, a remission rate of 5-10%, is only identified in 
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individuals with severe depression72. In the end, it would most likely come down to cost 
when deciding which of these two classes to use.  
 TCAs are one of the earlier forms of antidepressants, discovered through clinical 
observations. They have mechanisms similar to SSRIs and SNRIs: by enhancing 
serotonergic and/or noradrenergic levels. However, in the process of blocking 5-HT and 
NE reuptake, TCAs also antagonize histaminergic, cholinergic, and alpha1-adrenergic 
receptor sites. This causes unwanted side effects such as weight gain, dry mouth, 
constipation, and dizziness. Cardiovascular effects are common, restricting treatment 
dosing. Overdose can lead to an eventual complete heart block73.  While the use of TCAs 
is less attractive in comparison to SSRIs and SNRIs, certain researchers argue TCAs may 
be a viable choice for mothers with post- or pre-natal depression not responding to those 
other medications. Treatment efficacy has been shown to be tied to serum levels and 
level-to-dose ratio varies greatly among individuals. Metabolism and hormonal changes 
must be monitored with dosing changes accordingly66.  
 MAOIs are another “first generation” anti-depressant medications. They act by 
blocking the monoamine oxidase enzyme, which is responsible for breaking down several 
neurotransmitters in the brain such as 5-HT, NE, and DA. Due to several dietary 
restrictions, side effects, and safety concerns, this treatment option is only used when all 
others are unsuccessful. Common complaints by users are similar to those receiving 
TCAs74. MAOIs prevent the breakdown of tyramine, which can build up if the 
individual’s diet is rich in tyramine. This will lead to high blood pressure, and may rarely 
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trigger a cerebral hemorrhage. While oral intake is more common, skin patches exist and 
can be more beneficial. Transdermal use limits the dosing, resulting in fewer side 
effects75. The use of MAOI for the treatment of PPD is unusual. 
 
C. Self-care  
 
An emerging trend is a holistic treatment method and focus for PPD.  Yoga has 
been proposed as a form of alternative medicine. It is interpreted to be a mind-body 
practice that promotes physical and mental wellness.  Aside from depression, yoga has 
proven health benefits such as lowering blood pressure and cortisol levels, increasing 
blood flow, and reducing anxiety. Data from meta-analyses showed yoga was beneficial 
as a complementary form of treatment and therapy. In groups that did not see significant 
change, they did note the practice prevented an increase in depressive symptoms76.   
With the concern of rising health care costs in certain countries and many women 
refusing to receive mental health counseling, focus on self-help has increased. Pre-natal 
yoga is a form of yoga tailored to be safe and gentle for pregnant women. Nonjudgmental 
attention is an important intention they carry, reducing any negative self-judgment. Two 
randomized control trials studied the effects of pre-natal yoga on pregnant women based 
on self-report scales. The women noted positive outcomes and based off of their scores, 
improvements were similar to having brief social support conditions57. A separate 
randomized control trial by Buttner et al. compared yoga practice to a placebo group.  
Over two months, sixteen yoga classes were attended by half of the cohort. Outcomes 
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that were scored by the end of the two months include depression, anxiety, and health-
related quality of life levels. The yoga group experienced significantly greater rate of 
improvement in comparison to the placebos, with moderate to large effects77.  
Mindfulness-based interventions (MBIs) can be found through yoga practices as 
well as in intervention groups. This could be a cost-effective alternative to therapy or 
medication. MBIs are brief, on average lasting eight sessions, delivered in a group 
setting. Mindfulness meditation practice is incorporated with a nonjudgmental mindset 
foundation. This form of therapy may only be effective for mothers with mild to 
moderate PPD. MBIs ask participants to bring their full awareness to the present moment. 
Individuals with severe depression would likely have automatic aversive thoughts and 
unpleasant emotions. Sitting in this negative mental state would likely worsen their 






 The diagnosis of PPD is better studied and understood in comparison to just 
twenty years ago. Generations of drugs have evolved and developed. While the standard 
method of care revolves around the same first-line treatment manners, controversy arises 
in the true effectiveness and variables amongst individuals. Albeit similar in the diagnosis 
and treatment of MDD, care must be given to aftereffects that not only harm the mother’s 
ever-changing biology postpartum, but also the newborn.   
 Risk factors of PPD include several environmental factors, such as the mother’s 
demographics. Many research studies have looked into the effect of mother’s SES on the 
risk of PPD. Those same studies concluded this small but significant factor does indeed 
contribute to PPD. However, other literature argues otherwise and/or show limitations in 
their studies. As Goyal et al., noted, the cut-off of what is deemed low-income is a 
relative number that can be applied to a specific sector, but cannot be used to generalize 
the entire country, let alone globally46.  SES is a vague term, especially with the potential 
fluidity in employment status during the transition to motherhood. Single mothers would 
render different results if compared to women on maternal leave or has the financial 
support from spouse.  
Income is simply one dimension of SES. This discrepancy leaves room for larger 
studies in different parts of the world. Adewuya et al. reported SES and education level 
had no significant influence between depressed and non-depressed mothers78. 
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Confounding factors such as the cost of living, average household income, and health 
care coverage vary depending on the country. Further meta-analyses could then truly 
analyze whether SES is a significant environmental risk factor of PPD.  
Biological dispositions have allowed specific pathways or physiological systems 
to be the target of treatment. A much-studied area is the SERT gene and its relation to 
depression, either alone or in conjunction with stressful environmental factors. However, 
its actual contribution to depression remains questionable. Literatures with a similar 
course of initial promise end in inconsistent patterns of replications and non-replications. 
Whole genome approaches have provided novel insight on the actual mechanisms 
involved with depression. The genetic architecture is comprised of many common 
variants that alone, have small effects. There is a smaller number of rare variants with 
larger effect, but even combined do not have as large an effect as mentioned in other 
studies79. Whole genome methods need to be further analyzed in order to truly understand 
the connection between the SERT gene and depression. 
 Another biological area of study involves the HPA axis. Overstimulation of the 
HPA axis has been linked to various mood disorders; lack of negative feedback loop 
causes an accumulation of cortisol, also known as the stress hormone. While this 
knowledge has long been known, no drug directly targeting HPA axis components have 
been approved. A thoroughly studied area of MDD, there is evidence that not all 
depressed individuals have HPA axis alterations80. Further studies on the genetic 
component of depression predisposition in relation to the HPA axis could lead to 
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precision medicine in the future. This would diminish side effects and allow for 
antidepressant prescriptions to be tailored to each individual patient.    
 Antidepressant medication presents a tricky role in the treatment of PPD. With 
many generations of improvements, high success rates in treating depression have made 
it an exceptionally viable option for individuals with moderate to severe depression; 
however, extra precautions are necessary with pregnant or breastfeeding women. 
Breastfeeding has been documented to have both short- and long-term health benefits for 
mother and child. These benefits must be weighed carefully against the effects of 
untreated PPD and the consequences of prescribing antidepressants to the mother. All 
antidepressants are passed from maternal plasma to breast milk. However, when maternal 
illness clearly interferes with self-care or care of the newborn, pharmacological 
intervention must be considered. Mothers who still insist on breastfeeding while on low-
dose anti-depressants would need to be closely monitored along with their newborn. 
Pumping and discarding breast milk during periods of  peak drug concentrations is 
suggested, but there is not enough research to confirm whether this is significantly 
beneficial4. Major fetal malformation and persistent pulmonary hypertension in the 
neonate has been associated with SSRI use during late pregnancy. The treatment of 
mental health in mothers during and post pregnancy must be examined. At the moment, 
in-person psychotherapy and counseling appear to be the best solution with the least 
amount of side effects; nonetheless, this may not be an adequate option for severe PPD. 
Treatment methods with just as high success rates as antidepressants, such as online 
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therapy, is an area that requires further research in order to ensure the best mental and 
physical health for mothers and their newborns. 
 Antidepressants are often the first-line treatment for MDD, and more commonly 
used to treat PPD now compared to the past. Overall, psychologic treatments demonstrate 
moderate effect sizes, while antidepressants demonstrate larger effect sizes81. SSRIs are a 
popular class of antidepressant without the side effects and restrictions observed in the 
use of TCAs or MAOIs. Apart from the concern of use while breastfeeding, animal 
models have inconsistently shown that SSRIs alter maternal caregiving behaviors. Rats 
treated with SSRIs postpartum show less passive nursing and less nest building82.  
Meanwhile, other studies have found SSRI use during gestation and postpartum can 
increase nursing in rat dams, but not in mouse dams83. The discrepancy between these 
two mammalian models have not been studied further. If a genetic or species factor 
explains this hormonal disparity, it brings about the question the validity of the animal 
models when studying PPD treatments. The actual application of this knowledge onto 
human subjects will require further investigation.  
 Although antidepressants and psychotherapy are effective independently, 
combined therapy is provided to individuals with severe depression. This same treatment 
may be just as beneficial to individuals with mild to moderate PPD.  A meta-analysis 
performed by Cuijpers et al. found clear evidence that combined treatment is more 
effective than medication alone84. As of now, it is unclear whether the effects of 
pharmacotherapy and psychotherapy complement each other or have effects independent 
 
44 
of each other. While this one meta-analysis appears to show both treatments contributing 
equally, larger cohort studies must be performed to examine how much more effective 
combined therapy is in comparison to independent treatments. Time and cost are two 
factors that most new mothers struggle with. The likelihood of them choosing combined 
therapy is lower if the efficacy of one treatment is similar to that of a combined 
treatment.  
 The concept of antidepressant use and psychotherapy are still taboo in many 
cultures, leaving many mothers’ mental health conditions unattended. This taboo is lined 
with false beliefs that needing any mental health assistance is equivalent to being 
clinically insane. The effectiveness of antidepressants and therapy is then lost and 
become meaningless options to mothers with PPD. Persons of color are less likely  to 
seek mental health services compared to European Americans, with Asian Americans 
dropping out of mental health treatments at an extremely high rate85. While mindfulness 
and self-care practices are comparatively new concepts, they may be viable options for 
mothers refusing mental health treatment. Due to the Asian roots of the philosophies, 
mindfulness and acceptance-based psychotherapies are promising alternatives to Asian 
patients.  Although research shows conflicting results as to whether yoga and 
mindfulness-based practices can eradicate depression, they do show no increase in 
depressive symptoms after consistent practice. This should only be suggested as a last 
resort treatment if the patient persists on not receiving any mental health care. Online 
psychotherapy sessions are gaining popularity, both for the easy accessibility and the 
ability to have it at the privacy of one’s own home. Research has shown online sessions 
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to be just as efficient as in-person sessions; for severe PPD patients reluctant to receive 
mental health, online psychotherapy may be the answer. 
 Another treatment method that has been highly contested is ECT. According to a 
few small studies, ECT appears to be most effective during the postpartum period in 
comparison to other periods of life86. The response rate of ECT is also markedly higher 
than SSRI treatment (59% versus 26% respectively)87. Overall, cases that received ECT 
early after delivery had better results; it is unsure whether this is a confounding variable 
since mothers who received treatment earlier are also more severe cases. Treatment 
results for moderate PPD subjects were similar to those achieved with 
pharmacotherapy86.  
 ECT would be a viable option to alleviate moderate PPD if those individuals are 
not responding to medications or simply want a faster response. This is an especially 
important consideration for mothers who want to continue breastfeeding. Risk factors 
mothers will need to consider the risk of relapse and a short period of memory loss. Time 
to relapse decreases with the number of previous episodes and age; the first month of 
delivery correlates with an increased risk.  Memory disturbance can be either anterograde 
or retrograde88. While it is a temporary adverse effect that lasts for a few days at most, 







 Although PPD is very common, understanding its pathogenesis requires further 
exploration and analysis. Even though some triggering factors are similar to those 
eliciting MDD, the risk factors and biological mechanisms are different. Treatment 
options currently available are efficacious with mothers that have varying degrees of PPD 
severity. These treatments have been used based on their efficacy in treating MDD, 
which at times is comorbid with other mental health issues. Alternatives need to be 
available, especially for mothers with severe PPD. Psychotherapy and antidepressants 
have shown to alleviate depressive symptoms and style of living for patients with mild to 
moderate PPD. Women with severe PPD that breastfeed must receive low doses of 
medication or consider other options such as ECT.  
 Meta-analyses in small randomized control samples have limited informative 
value and large-scale studies exploring samples from different countries may provide a 
better insight on risk factors that contribute to PPD and how to better improve treatment. 
Several studies have noted similar confounding variables, such as socio-economic status, 
education level and what mothers define as support. More studies must be carried out in 
order to reach a more comprehensive understanding of mechanisms involved in the 
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